Chase Pharmaceuticals Corporation
Records under this name other than the patents Chase Pharmaceuticals Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 7 of 7 · Back to Chase Pharmaceuticals Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,149,828 | Oxybutynin Transdermal Therapeutic System Combination No holder on record In force · High confidence | In force | High confidence | |
| US 9,913,836 | Anticholinergic neuroprotective composition and methods Lapsed on the fee record Ended Mar 13, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 13, 2026 | USPTO record |
| US 9,896,416 | Piperidinium quaternary salts Lapsed on the fee record Ended Feb 20, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 20, 2026 | USPTO record |
| US 9,744,161 | Method and composition for treating alzheimer-type dementia Lapsed on the fee record Ended Aug 29, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 29, 2025 | USPTO record |
| US 9,561,218 | Anticholinergic neuroprotective composition and methods Lapsed on the fee record Ended Feb 7, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 7, 2025 | USPTO record |
| US 10,596,139 | Oxybutynin transdermal therapeutic system muscarinic agonist combination Lapsed on the fee record Ended Mar 24, 2024 · USPTO record | Lapsed on the fee record | Ended Mar 24, 2024 | USPTO record |
| US 10,548,855 | Memantine combinations and use Lapsed on the fee record Ended Feb 4, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 4, 2024 | USPTO record |